A Study of the Safety and Effectiveness of Benralizumab to Treat Patients With Severe Uncontrolled Asthma.
Status:
Completed
Trial end date:
2020-10-21
Target enrollment:
Participant gender:
Summary
The purpose of this study is to investigate the effect of benralizumab on the rate of asthma
exacerbations, patient reported quality of life and lung function during the 24-week
treatment in patients with uncontrolled, severe asthma with an eosinophilic phenotype. A
subset of patients will be assessed for their ongoing chronic rhinosinusitis with nasal
polyps. The study design has been updated to include a 56-week open label ANDHI in Practice
(ANDHI IP) sub study upon the completion of the 24-week double-blind period of the ANDHI
study.